The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

被引：58
|
作者：
Tzavara, ET [1 ]
Perry, KW [1 ]
Rodriguez, DE [1 ]
Bymaster, FP [1 ]
Nomikos, GG [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2001年 / 426卷 / 03期
关键词：
microdialysis; norepinephrine; SR141716A;
D O I：
10.1016/S0014-2999(01)01228-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The effects of the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo microdialysis in the anterior hypothalamus of freely moving rats. SR14716A (0.3, 1, 3 mg/kg, i.p.) dose-dependently increased norepinephrine efflux to about 300% of baseline, without affecting 5-HT levels. This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码：R3 / R4
页数：2
相关论文
共 50 条
  • [41] Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys
    Beardsley, PM
    Dance, ME
    Balster, RL
    Munzar, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 435 (2-3) : 209 - 216
  • [42] Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist
    Torbjörn U. C. Järbe
    Michele Y. Harris
    Chen Li
    Qian Liu
    Alexandros Makriyannis
    Psychopharmacology, 2004, 177 : 35 - 45
  • [43] Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant)
    Carai, MAM
    Colombo, G
    Gessa, GL
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 494 (2-3) : 221 - 224
  • [44] Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors
    MacLennan, SJ
    Reynen, PH
    Kwan, J
    Bonhaus, DW
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (04) : 619 - 622
  • [45] SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists
    Costa, B
    Colleoni, M
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (12): : 1103 - 1108
  • [46] Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs
    Thomas, Brian F.
    Zhang, Yanan
    Brackeen, Marcus
    Page, Kevin M.
    Mascarella, S. Wayne
    Seltzman, Herbert H.
    AAPS JOURNAL, 2006, 8 (04): : E665 - E671
  • [47] Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs
    Brian F. Thomas
    Yanan Zhang
    Marcus Brackeen
    Kevin M. Page
    S. Wayne Mascarella
    Herbert H. Seltzman
    The AAPS Journal, 8
  • [48] Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat
    Navarro, M
    Hernandez, E
    Munoz, RM
    delArco, I
    Villanua, MA
    Carrera, MRA
    deFonseca, FR
    NEUROREPORT, 1997, 8 (02) : 491 - 496
  • [49] CB1 receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord
    Lever, IJ
    Malcangio, M
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) : 21 - 24
  • [50] Behavioral mechanisms underlying the hypophagic effect of the cannabinoid CB1 receptor antagonist SR 141716A in rats
    Schreiber, R
    De Vry, J
    BEHAVIOURAL PHARMACOLOGY, 2003, 14 : S48 - S48
12345